molecules molecules molecules molecules molecules molecules
The Arcus Vision

How do Biotechs Stay the Course in Uncharted Waters?

By Beyond Borders   |   EY biotechnology report 2022

Reading Time: minutes

EY biotechnology report 2022

Beyond Borders excerpt: This 32nd edition of our Beyond Borders report offers a chance to take stock of the biotechnology (biotech) industry’s impressive performance during a period of intense global disruption. When, five years ago, we last published our Beyond Borders overview of the sector, we noted the growing geopolitical complexities set to impact biotech. Titling our 2017 report “Staying the course,” we observed that the industry would have to navigate a business environment in which, increasingly, “uncertainty is the only certainty.” From the perspective of 2022, we can affirm that biotech has indeed successfully stayed the course, despite the upheavals that have affected global business since the last edition of this report.

Read the report in its entirety here.


Our Science|January 10, 2024

The Fc-silent Treatment: Pursuing a Known Target in a New Way

We were among the first to take a different approach and pursue an Fc-silent anti-TIGIT antibody based on our own scientific understanding of how this biological pathway works.

Juan Jaen, Ph.D.|President at Arcus Biosciences
Read More
Life at Arcus|December 4, 2023

“Cricket is Life in a Nutshell”: Arcus Executive Arun Tholudur Talks Longtime Passion for Cricket, How it Intersects with Drug Development

Arun Tholudur is SVP, Pharmaceutical Development & Manufacturing at Arcus. We sat down with him to discuss his love for playing cricket, his experience playing on the Masters Cricket USA National Cricket Team, and how lessons he’s learned from the sport apply to his work here at Arcus.

Sophia Vraciu|Arcus Biosciences
Read More